Journal of Infertility and Reproductive Biology

Journal of Infertility and Reproductive Biology, 2023, Volume 11, Issue 4, Pages: 88-91

Polycystic Ovary Syndrome as a Variant of Metabolic Syndrome- A Review Article

Raisa A. Aringazina[1]*, Piyush Sharma[2], Amrender Singh[3], Maryam Ekramzadeh[4]

1. Department of Internal Diseases No. 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
2. General Medicine Faculty, Sub-Internal Diseases, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
3. General Medicine Faculty, Sub-Internal Diseases, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
4. Division of Nephrology and Hypertension, The Landquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA

Received: 03/10/2023 Accepted: 01/12/2023 Published: 20/12/2023

Abstract

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting 6–12% of women of reproductive age worldwide. It is primarily characterized by hormonal imbalances, irregular menstruation, and ovarian cysts. Recent studies, however, propose that PCOS extends beyond a reproductive condition and shares significant overlaps with metabolic syndrome. Metabolic syndrome is a cluster of risk factors, including insulin resistance, abdominal obesity, hypertension, and dyslipidemia, which collectively elevate the risk of cardiovascular diseases, diabetes, and other related complications. Insulin resistance, a hallmark of metabolic syndrome, is present in approximately 70% of women with PCOS. Elevated insulin levels foster fat accumulation, particularly around the abdomen, leading to visceral fat deposition. Dyslipidemia, another common metabolic disturbance in PCOS, involves high triglycerides and low high-density lipoprotein (HDL) cholesterol, further linking the condition to metabolic syndrome. Hormonal imbalances in PCOS, particularly increased androgen levels, intensify these metabolic disruptions, contributing to symptoms such as acne, weight gain, and hirsutism. The overlap between PCOS and metabolic syndrome underscores the need for comprehensive management strategies addressing both reproductive and metabolic health. Lifestyle changes, such as adopting a balanced diet and regular physical activity, are essential for improving insulin sensitivity and mitigating cardiovascular risks. Pharmacological interventions, like metformin to combat insulin resistance, and anti-androgen medications to manage hormonal symptoms, may complement lifestyle modifications. By recognizing the metabolic dimensions of PCOS, healthcare professionals can develop targeted, personalized treatment plans that improve reproductive health while reducing the risk of chronic conditions such as type 2 diabetes, heart disease, and infertility. A holistic approach to managing PCOS can enhance patient outcomes, ensuring better long-term health and quality of life for affected women.

Keywords: Polycystic ovary syndrome, Metabolic syndrome, Insulin resistance, Inflammation, Hyperandrogenism

Introduction

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Traditionally viewed as a reproductive issue, PCOS has gained recognition as a condition with profound metabolic consequences. Women with PCOS are predisposed to developing metabolic syndrome, defined by a constellation of insulin resistance, obesity, hypertension, and dyslipidemia. The connection between PCOS and metabolic syndrome highlights the importance of an integrated diagnostic and therapeutic approach (1,2). Beyond the immediate impact on fertility, PCOS significantly increases long-term risks for type 2 diabetes, cardiovascular disease, and other systemic conditions. This review discusses the overlapping mechanisms and implications, emphasizing the importance of comprehensive care (3, 4).

This review aims to evaluate the shared pathophysiological mechanisms between PCOS and metabolic syndrome and to propose holistic diagnostic and therapeutic approaches. It emphasizes the importance of addressing both reproductive and metabolic dimensions to enhance patient care.

Materials and Methods

This narrative review is based on an analysis of peer-reviewed studies sourced from databases like PubMed, Scopus, and Google Scholar. Articles published between 1990 and 2023 were considered, focusing on the interconnections between PCOS and metabolic syndrome, including shared mechanisms, clinical manifestations, and management strategies. Data from clinical guidelines and consensus statements were also included to provide evidence-based recommendations.

Results

Shared Pathophysiological Mechanisms

- Observed in up to 80% of women with PCOS, plays a central role in both metabolic and reproductive

***Corresponding author:** Raisa A. Aringazina, Department of Internal Diseases No. 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan, Email: raisa_aringazina@mail.ru

dysfunction. Elevated insulin levels stimulate androgen production by ovarian theca cells, intensifying hyperandrogenism. This leads to irregular ovulation, impaired glucose uptake, and increased visceral fat deposition.

Studies suggest that even women with PCOS and normal weight demonstrate insulin resistance, indicating a genetic or hormonal predisposition.

- Moreover, PCOS is independently associated with an increased incidence of type 2 diabetes mellitus (T2DM) in both obese and nonobese women. Research conducted in Korea found that the incidence of newly diagnosed PCOS per 1,000 person-years among the cohort population revealed a higher risk for T2DM, highlighting the significant metabolic risk associated with the condition. This data emphasizes the need for early metabolic screening and intervention for women with PCOS to mitigate long-term health risks, such as diabetes (5, 6, 7).
- Chronic Inflammation: Pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), are elevated in both PCOS and metabolic syndrome. These cytokines disrupt endothelial function, contributing to vascular complications. Furthermore, oxidative stress, marked by excessive reactive oxygen species (ROS), accelerates cellular damage and exacerbates insulin resistance (6,7).
- Adipose Tissue Dysfunction:Visceral fat, more metabolically active than subcutaneous fat, is prevalent in PCOS. It contributes to increased secretion of adipokines like leptin, which becomes resistant, and reduced levels of adiponectin, which supports glucose metabolism. This imbalance promotes systemic inflammation and worsens hormonal irregularities (8).
-



Figure 1. Cumulative probability of PCOS occurrence. (14) https://pmc.ncbi.nlm.nih.gov/articles/PMC3309040

Clinical Manifestations

- Metabolic abnormalities such as impaired glucose tolerance, dyslipidemia (elevated triglycerides and reduced HDL cholesterol), and hypertension are common in PCOS. These features significantly elevate cardiovascular risks, including arterial stiffness and early atherosclerosis, which are often subclinical but progressive.
- Hyperandrogenism remains a defining feature of PCOS, causing hirsutism, acne, and alopecia, all of which impact quality of life. Ovulatory dysfunction manifests as irregular menstrual cycles or infertility, while prolonged unopposed estrogen exposure increases the risk of endometrial hyperplasia and carcinoma (9).

3. Management Approaches

- Life style Interventions: Lifestyle changes are the cornerstone of managing both PCOS and metabolic syndrome.
  - Diet: A low glycemic index diet improves insulin sensitivity and enhances ovulatory function. The Mediterranean diet has shown promise in reducing inflammation and improving cardiovascular markers.
  - Exercise: Regular physical activity, including aerobic and resistance training, reduces visceral fat and improves glucose metabolism. Studies indicate that moderate-intensity exercise for 150 minutes per week significantly benefits metabolic and reproductive health.
  - Weight Management: Even a 5–10% reduction in body weight can lead to improved insulin sensitivity, regular menstrual cycles, and reduced androgen levels (2, 6).

- **Pharmacological Treatments**
  - Metformin, an insulin-sensitizing agent, improves insulin resistance, lowers androgen levels, and enhances menstrual regularity in women with PCOS. As shown in Figure 2, metformin significantly increases ovulation rates over six months compared to placebo, with the Combination Group also showing improved outcomes. This highlights the benefit of metformin in improving reproductive health in PCOS. Hormonal Therapies: Combined oral contraceptives (COCs) regulate menstrual cycles, reduce acne, and address hirsutism by lowering androgen levels.
  - Anti-androgens: Spironolactone and similar drugs alleviate symptoms of hyperandrogenism, such as hirsutism and alopecia (10).
- Emerging Therapies:Novel approaches include targeting the gut microbiome to reduce systemic inflammation and exploring anti-inflammatory agents to counter cytokine overproduction. Personalized medicine, leveraging genetic and epigenetic insights, promises tailored interventions for more effective management (11,12,13).
-



Figure 2. The positive effect of proper PCOS treatment (15) https://pubmed.ncbi.nlm.nih.gov/25333031/.

Animal Models for Understanding PCOS as a Variant of Metabolic Syndrome

Animal models have been pivotal in elucidating the complex interplay between reproductive and metabolic pathways in PCOS (16). Rodent models, particularly those induced by androgens like dihydrotestosterone or letrozole, replicate key phenotypes of human PCOS, including hyperandrogenism, anovulation, and insulin resistance (17, 18). These models highlight the role of androgen excess in driving both reproductive and metabolic dysfunctions, enabling researchers to explore the causal mechanisms underlying the condition.

Metabolic Dysregulation in Animal Models

Rodents with PCOS-like traits often exhibit hallmark features of metabolic syndrome, such as impaired glucose tolerance, dyslipidemia, and visceral adiposity (19). Insulin resistance is a central feature observed in these models, manifesting through disrupted insulin signaling pathways in the liver, and adipose tissue (20, 21).

Chronic Inflammation and Adipose Tissue Dysfunction

Pro-inflammatory cytokines are consistently elevated in PCOS models, mirroring findings in human studies. Adipose tissue in these models shows a shift towards a pro-inflammatory state, characterized by macrophage infiltration and dysregulated adipokine secretion (22, 23). This adipose dysfunction contributes significantly to systemic inflammation and exacerbates both metabolic and reproductive abnormalities (22).

Therapeutic Insights from Animal Studies

Animal studies have provided critical insights into potential therapeutic interventions. Treatment with insulin-sensitizing agents like metformin or pioglitazone has been shown to mitigate insulin resistance and restore ovulatory function in rodent models (24, 25). Similarly, anti-inflammatory strategies, including the administration of antioxidants and cytokine inhibitors, have demonstrated efficacy in reducing systemic inflammation and improving metabolic health (26, 27).

Emerging research in animal models focuses on the gut microbiota's role in PCOS pathogenesis. Alterations in gut microbial composition have been linked to systemic inflammation and metabolic dysregulation (28). Probiotic and prebiotic interventions are being explored as novel therapeutic avenues to restore metabolic balance in PCOS (29).

Conclusion

Polycystic ovary syndrome and metabolic syndrome share intricate pathophysiological mechanisms, including insulin resistance, chronic inflammation, and adipose tissue dysfunction. These interconnected factors drive both the reproductive and metabolic disturbances observed in PCOS, demanding a holistic approach to diagnosis and treatment (1).

Recognizing PCOS as a metabolic syndrome variant represents a paradigm shift, emphasizing the need for integrated care. Addressing metabolic concerns such as insulin resistance, dyslipidemia, and cardiovascular risks alongside reproductive issues like hyperandrogenism and anovulation provides a comprehensive framework for management.

Emerging research into biomarkers, innovative therapies, and long-term outcomes promises to revolutionize the treatment of PCOS. Advances in gene editing, regenerative medicine, and targeted metabolic modulators hold significant potential to improve patient care. Simultaneously, lifestyle interventions, including diet, exercise, and weight management, remain indispensable in preventing disease progression and enhancing quality of life.

By prioritizing both metabolic and reproductive health, this integrated approach will drive better clinical outcomes, ultimately improving the long-term well-being of women affected by PCOS. Notably, research from Korea has shown that PCOS is independently associated with an increased risk of type 2 diabetes, even in nonobese women, further highlighting the importance of metabolic monitoring and early intervention (6, 10).

References

1. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544-51.
2. Cowan S, Lim S, Alycia LJ, Morgan. Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocr Disord. 2023;23(14).
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7.
4. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.
5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800. doi: 10.1210/edrv.18.6.0318.
6. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 2006;113(10):1148-59.
7. Ryu KJ, Kim M, Kyun Kim H, Jin Kim MD, Wook Yi K, et al. Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study. Fertil Steril. 2021;115(6):1569-75.
8. Gao Y, Zou Y, Wu G, Zheng L. Oxidative stress and mitochondrial dysfunction of granulosa cells in polycystic ovary syndrome. Front Med (Lausanne). 2023;10:1193749. doi: 10.3389/fmed.2023.1193749.
9. Zhang J, Bao Y, Zhou X, Zheng L. Polycystic ovary syndrome and mitochondrial dysfunction. Reprod Biol Endocrinol. 2019;17:67.
10. Moran LJ, Ko H, Misso M, Marsh K, Noakes M, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet. 2013;113(4):520-45.
11. Tremellen K, Pearce K. Dysbiosis of gut microbiota (DOGMA) – a novel theory for the development of

polycystic ovarian syndrome. Med Hypotheses. 2012;79(1):104-12.
12. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13.
13. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88.
14. González F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2011;77(4):300–305.
15. Johnson NP. Metformin use in women with polycystic ovary syndrome. Ann Transl Med. 2014;2(6):56.
16. Alaee S, Bagheri MJ, Ataabadi MS, Koohpeyma F. Capacity of Mentha spicata (spearmint) extracts in alleviating hormonal and folliculogenesis disturbances in a polycystic ovarian syndrome rat model. World's Veterinary Journal. 2020;3:451-6.
17. Ataabadi MS, Bahmanpour S, Yousefinejad S, Alaee S. Blood volatile organic compounds as potential biomarkers for polycystic ovarian syndrome (PCOS): An animal study in the PCOS rat model. The Journal of Steroid Biochemistry and Molecular Biology. 2023 1;226:106215.
18. Lohrasbi P, Karbalay-Doust S, Tabei SM, Azarpira N, Alaee S, Rafiee B, Bahmanpour S. The effects of melatonin and metformin on histological characteristics of the ovary and uterus in letrozole-induced polycystic ovarian syndrome mice: A stereological study. International Journal of Reproductive BioMedicine. 2022;20(11):973.
19. Maliqueo M, Benrick A, Stener-Victorin E. Rodent models of polycystic ovary syndrome: phenotypic presentation, pathophysiology, and the effects of different interventions. Seminars in Reproductive Medicine. 2014;32(3):183-93.
20. Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models to disease mechanisms. The Journal of Endocrinology. 2014;220(2):T1.
21. Kubota T, Kubota N, Kadowaki T. Imbalanced insulin actions in obesity and type 2 diabetes: key mouse models of insulin signaling pathway. Cell Metabolism. 2017;25(4):797-810.
22. Marino JS, Iler J, Dowling AR, Chua S, Bruning JC, Coppari R, Hill JW. Adipocyte dysfunction in a mouse model of polycystic ovary syndrome (PCOS): evidence of adipocyte hypertrophy and tissue-specific inflammation. PLOS ONE. 2012;31;7(10):e48643.
23. Bril F, Ezeh U, Amiri M, Hatoum S, Pace L, Chen YH, Bertrand F, Gower B, Azziz R. Adipose tissue dysfunction in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2024;109(1):10-24.
24. Kupreeva M, Diane A, Lehner R, Watts R, Ghosh M, Proctor S, Vine D. Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. American Journal of Physiology - Endocrinology and Metabolism. 2018.
25. Wu Y, Li P, Zhang D, Sun Y. Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway. Experimental and Therapeutic Medicine. 2018;15(2):2120-7.
26. Darabi P, Khazali H, Mehrabani Natanzi M. Therapeutic potentials of the natural plant flavonoid apigenin in polycystic ovary syndrome in rat model: via modulation of pro-inflammatory cytokines and antioxidant activity. Gynecological Endocrinology. 2020;36(7):582-7.
27. Rafiee B, Karbalay-Doust S, Tabei SM, Azarpira N, Alaee S, Lohrasbi P, Bahmanpour S. Effects of N-acetylcysteine and metformin treatment on the stereopathological characteristics of uterus and ovary. European Journal of Translational Myology. 2022;32(2).
28. Rodriguez Paris V, Wong XY, Solon-Biet SM, Edwards MC, Aflatounian A, Gilchrist RB, Simpson SJ, Handelsman DJ, Kaakoush NO, Walters KA. The interplay between PCOS pathology and diet on gut microbiota in a mouse model. Gut Microbes. 2022;14(1):2085961.
29. Kaur I, Suri V, Sachdeva N, Rana SV, Medhi B, Sahni N, Ahire J, Singh A. Efficacy of multi-strain probiotic along with dietary and lifestyle modifications on polycystic ovary syndrome: a randomized, double-blind placebo-controlled study. European Journal of Nutrition. 2022;61(8):4145-54.